Horm Metab Res 2020; 52(05): 264-279
DOI: 10.1055/a-1143-6024
Review
© Georg Thieme Verlag KG Stuttgart · New York

Association of VEGF Gene Polymorphisms with Susceptibility to Diabetic Retinopathy: A Systematic Review and Meta-Analysis

Qianhui Yang
1   Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Medical University Eye Hospital, Tianjin, China
,
Yan Zhang
1   Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Medical University Eye Hospital, Tianjin, China
,
Xiaomin Zhang
1   Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Medical University Eye Hospital, Tianjin, China
,
Xiaorong Li
1   Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Medical University Eye Hospital, Tianjin, China
,
Juping Liu
1   Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Medical University Eye Hospital, Tianjin, China
› Author Affiliations
Further Information

Publication History

received 13 November 2018

accepted 11 March 2020

Publication Date:
13 May 2020 (online)

Abstract

The associations between vascular endothelial growth factor (VEGF) gene polymorphisms and risk of type 2 diabetic retinopathy (DR) – proliferative diabetic retinopathy (PDR), and nonproliferative diabetic retinopathy (NPDR) – remain unclear. A systematic search and meta-analysis using odds ratio (OR) with 95% confidence interval (CI) was performed to evaluate the association. Our study concluded 26 studies containing 10 single nucleotide polymorphisms (SNPs). In Asian populations, rs3025039 polymorphism was associated with DR risk, while in overall populations and Caucasians, the DR risk was increased by association with rs2010963. There was a significant association between rs25648 and rs833061 and DR risk in Caucasians. DR risks were found to be significantly associated between rs3025021, rs13207351, and rs2146323 in either overall populations, Caucasians or Asians. Besides, in overall and Asian populations, rs699947 and rs3025039 were associated with PDR risk. rs1570360, rs3025039, and rs833061 played a key role in PDR etiology in Caucasians. rs2010963 was associated with increased risk of PDR in overall populations. A significant association between rs699947, rs3025039, and rs833061 and NPDR risk in overall populations and Asians was found. A significant association was observed between rs2010963 and increased NPDR risk in overall and Caucasian populations. This study provides a new insight into the parthenogenesis of diabetic retinopathy. Targeting VEGF SNPs may be a potential of therapeutic approach for the treatment of DR, PDR, and NPDR.

 
  • References

  • 1 Gonzalez-Salinas R, Garcia-Gutierrez MC, Garcia-Aguirre G. et al. Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population. Int J Ophthalmol 2017; 10: 135-139
  • 2 Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000; 77: S113-S119
  • 3 Sami W, Ansari T, Butt NS. et al. Effect of diet on type 2 diabetes mellitus: A review. Int J Health Sci 2017; 11: 65-71
  • 4 Abu Al-Halaweh A, Davidovitch N, Almdal TP. et al. Prevalence of type 2 diabetes mellitus complications among palestinians with T2DM. Diabetes Metab Syndr 2017; 11 (Suppl 2) S783-S787
  • 5 Feghhi M, Nikzamir A, Esteghamati A. et al. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl Res 2011; 158: 85-91
  • 6 Chatziralli I, Sergentanis TN, Crosby-Nwaobi R. et al. Model for risk-based screening of diabetic retinopathy in people with newly-diagnosed type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2017. 58; Bio99-Bio105
  • 7 Yang Y, Andresen BT, Yang K. et al. Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp Biol Med (Maywood, NJ) 2010; 235: 1204-1211
  • 8 Larsen MB, Henriksen JE, Grauslund J. et al. Prevalence and risk factors for diabetic retinopathy in 17 152 patients from the island of Funen, Denmark. Acta Ophthalmol 2017; 95: 778-786
  • 9 Hampton BM, Schwartz SG, Brantley MA. et al. Update on genetics and diabetic retinopathy. Clin Ophthalmol (Auckland, NZ) 2015; 9: 2175-2193
  • 10 Dong L, Bai J, Jiang X. et al. The gene polymorphisms of IL-8(-251T/A) and IP-10(-1596C/T) are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population. Eye (London, England) 2017; 31: 601-607
  • 11 Yuan Y, Wen Z, Guan Y. et al. The relationships between type 2 diabetic retinopathy and VEGF-634G/C and VEGF-460C/T polymorphisms in Han Chinese subjects. J Diabetes Complicat 2014; 28: 785-790
  • 12 Porojan MD, Catana A, Popp RA. et al. The role of NOS2A -954G/C and vascular endothelial growth factor +936C/T polymorphisms in type 2 diabetes mellitus and diabetic nonproliferative retinopathy risk management. Therap Clin. Risk Manage 2015; 11: 1743-1748
  • 13 Abdel Fattah RA, Eltanamly RM, Nabih MH. et al. Vascular endothelial growth factor gene polymorphism is not associated with diabetic retinopathy in Egyptian patients. Middle East Afr J Ophthalmol 2016; 23: 75-78
  • 14 Shahin RM, Abdelhakim MA, Owid Mel S. et al. A Study of VEGF gene polymorphism in Egyptian patients with diabetic retinopathy. Ophthal Genet 2015; 36: 315-320
  • 15 Nakamura S, Iwasaki N, Funatsu H. et al. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefe Arch Clin Exp Ophthalmol 2009; 247: 21-26
  • 16 Petrovic MG, Korosec P, Kosnik M. et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 2008; 14: 1382-1387
  • 17 Szaflik JP, Wysocki T, Kowalski M. et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefe Arch Clin Exp Ophthalmol 2008; 246: 39-43
  • 18 Errera FI, Canani LH, Silva ME. et al. Functional vascular endothelial growth factor – 634G>C SNP is associated with proliferative diabetic retinopathy: A case-control study in a Brazilian population of European ancestry. Diabetes Care 2007; 30: 275-279
  • 19 Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I. et al. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrology, Dialysis, Transplantation: Official Publication of the Eur Dialy Transp Assoc 2007; 22: 827-832
  • 20 Suganthalakshmi B, Anand R, Kim R. et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006; 12: 336-341
  • 21 Awata T, Kurihara S, Takata N. et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005; 333: 679-685
  • 22 Ray D, Mishra M, Ralph S. et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004; 53: 861-864
  • 23 Awata T, Inoue K, Kurihara S. et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-1639
  • 24 Choudhuri S, Chowdhury IH, Das S. et al. Role of NF-kappaB activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy. Mol Cell Biochem 2015; 405: 265-279
  • 25 Paine SK, Basu A, Mondal LK. et al. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Mol Vis 2012; 18: 2749-2757
  • 26 Chun MY, Hwang HS, Cho HY. et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab 2010; 95: 3547-3551
  • 27 Kim HW, Ko GJ, Kang YS. et al. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. Nephrology (Carlton, Vic) 2009; 14: 681-688
  • 28 Abhary S, Burdon KP, Gupta A. et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 5552-5558
  • 29 Churchill AJ, Carter JG, Ramsden C. et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49: 3611-3616
  • 30 Yang X, Deng Y, Gu H. et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis 2011; 17: 3088-3096
  • 31 Kangas-Kontio T, Vavuli S, Kakko SJ. et al. Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br J Ophthalmol 2009; 93: 1401-1406
  • 32 Uthra S, Raman R, Mukesh BN. et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthal Genet. 2008; 29: 11-15
  • 33 Bleda S, De Haro J, Varela C. et al. Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients. Diabetes Vasc Dis Res 2012; 9: 68-74
  • 34 Xie XJ, Yang YM, Jiang JK. et al. Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: A meta-analysis. J Diabetes 2017; 9: 738-753
  • 35 Gong JY, Sun YH. Association of VEGF gene polymorphisms with diabetic retinopathy: A meta-analysis. PloS One 2013; 8: e84069
  • 36 Wang H, Cheng JW, Zhu LS. et al. Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians. Ophthal Res 2014; 52: 1-8
  • 37 Zhao T, Zhao J. Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2010; 90: 45-53
  • 38 Levin AM, Rusu I, Orlin A. et al. Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. Clin Ophthalmol (Auckland, NZ) 2017; 11: 193-200
  • 39 Wang JH, Ling D, Tu L. et al. Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?. Pharmacol Therap 2017; 173: 1-18
  • 40 Tolentino MJ, Miller JW, Gragoudas ES. et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820-1828
  • 41 Ip MS, Domalpally A, Sun JK. et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015; 122: 367-374
  • 42 Agarwal A, Ingham SA, Harkins KA. et al. The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics 2016; 17: 309-320
  • 43 Qiu M, Xiong W, Liao H. et al. VEGF -634G>C polymorphism and diabetic retinopathy risk: A meta-analysis. Gene 2013; 518: 310-315